InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,638.94
(
2.13%
)
US TECH 100
19,167.20
(
2.31%
)
Dow Jones
41,488.19
(
1.65%
)
Brent Oil
70.29
(
0.00%
)
Bitcoin
83,166.11
(
-1.40%
)
Post# of 254823
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 121290
Boards Moderated 8
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 204391

Monday, 09/19/2016 11:05:00 AM

Monday, September 19, 2016 11:05:00 AM

Post# of 254823
CLCD reports interim data from GLADIATOR—the open-label safety study of Lasmiditan for patients who participated in the SAMURAI* or SPARTAN† phase-3 efficacy trials:

http://finance.yahoo.com/news/correcting-replacing-colucid-pharmaceuticals-provides-144347284.html

CLCD has enrolled approximately 45% of the 2,580-patient enrollment goal for GLADIATOR. Interim safety data are detailed in the above PR.

--
*SAMURAI has been completed and it met all primary and secondary endpoints (#msg-124979400, #msg-125220925).

†SPARTAN, which has a similar design to SAMURAI and has an SPA, is expected to report data in 2H17.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up